Iron chelaton therapy with Deferasirox: Optimizing dosage and therapy initiation;Eisenchelat-Therapie mit Deferasirox: Therapiebeginn und Dosisoptimierung

Tumor Diagnostik und Therapie

Volumn 33, Issue 1, 2012, Pages 29-33

  Giagounidis, A ^a   Al Ali, H ^b   Mohr, A ^c   Haase, D ^d   Hofmann, W K ^e   Kreuzer, K A ^f   Gattermann, N ^g  

^a ST JOHANNES HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c Schwerpunktpraxis Onkologie Lerchenfeld   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

adherence; deferasirox; diarrhea; dosing; iron overload; tolerability

Indexed keywords

DEFERASIROX; IRON;

ARTICLE; DIARRHEA; DRUG MONITORING; DRUG TOLERABILITY; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; PHARMACOGENETICS; TREATMENT DURATION;

EID: 84856722811     PISSN: 0722219X     EISSN: 14391279     Source Type: Journal    
DOI: 10.1055/s-0031-1281866     Document Type: Article

References (35)

1. Porter JB. Deferasirox: an update. Hemoglobin: 2009; 33 01 70 S75
2. Cappellini MD. Long-term efficacy and safety of deferasirox. Blood Rev: 2008; 22 02 S35 S41
3. Piga A, Galanello R, Forni GL et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica: 2006; 91 873 880 (Pubitemid 44023139)
4. Chirnomas D, Smith AL, Braunstein J et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood: 2009; 114 4009 4013
5. Sechaud R, Robeva A, Belleli R et al. Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. J Clin Pharmacol: 2008; 48 919 925 (Pubitemid 352009486)
6. Novartis Pharma GmbH Exjade German prescribing information. 2010
7. Giagounidis A, Germing U, Aul C. Current treatment strategies in low-risk myelodysplastic syndromes. Cancer Treat Rev: 2007; 33 01 S19 S24 (Pubitemid 350056318)
8. Gattermann N, Finelli C, Porta MD et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res: 2010; 34 1143 1150
9. Pennell DJ, Porter JB, Cappellini MD et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Haematologica: 2011; 96 48 54
10. Borgna-Pignatti C, Rugolotto S, De Stefano P et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica: 2004; 89 1187 1193 (Pubitemid 39390442)
11. Fox F, Kundgen A, Nachtkamp K et al. Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only. Blood (ASH Annual Meeting Abstracts): 2009; 114 1747
12. Rose C, Brechignac S, Vassilief D et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res: 2010; 34 864 870
13. Cappellini MD, Cohen A, Piga A et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood: 2006; 107 3455 3462
14. Cappellini MD, Galanello R, Piga A et al. Efficacy and safety of deferasirox (Exjade) with up to 4. 5 years of treatment in patients with thalassemia major: a pooled analysis. ASH Annual Meeting Abstracts: 2008; 112 5411
15. Cappellini MD, Taher A, Vichinsky E et al. Efficacy and tolerability of deferasirox doses >30 mg/kg/day in patients with transfusion-dependent anemia and iron overload. Haematologica: 2008; 93 01 336 (abstract 845)
16. Cappellini MD, Porter J, El-Beshlawy A et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica: 2010; 95 557 566
17. Taher A, El-Beshlawy A, Elalfy MS et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol: 2009; 82 458 465
18. Exjade-Fachinformation. Novartis Pharma GmbH
19. Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol: 2008; 83 398 402 (Pubitemid 351614754)
20. Taher A, Cappellini MD, Vichinsky E et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol: 2009; 147 752 759
21. Gattermann N. Therapie der sekundären Hämochromatose. Dt Ärztebl Int: 2009; 106 499 504
22. Taher A, Al Jefri A, Elalfy MS et al. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. Acta Haematol: 2010; 123 220 225
23. Hershko C, Graham G, Bates GW et al. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol: 1978; 40 255 263 (Pubitemid 9040657)
24. Cabantchik ZI, Breuer W, Zanninelli G et al. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol: 2005; 18 277 287 (Pubitemid 40298370)
25. Pootrakul P, Breuer W, Sametband M et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood: 2004; 104 1504 1510 (Pubitemid 39166531)
26. List AF, Baer MR, Steensma D et al. Iron Chelation with Deferasirox (Exjade) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS). ASH Annual Meeting Abstracts: 2008; 112 634
27. Porter JB, Cappellini MD, El-Beshlawy A et al. Effect of deferasirox (Exjade) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective 1-year EPIC trial. Blood (ASH Annual Meeting Abstracts): 2008; 112 3881
28. Daar S, Pathare A, Nick H et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol: 2009; 82 454 457
29. List AF, Baer MR, Steensma D et al. Deferasirox (ICL670; Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS). ASH Annual Meeting Abstracts: 2007; 110 1470
30. Greenberg PL, Koller CA, Cabantchik ZI et al. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res: 2010; 34 1560 1565
31. Zanninelli G, Breuer W, Cabantchik ZI. Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients. Br J Haematol: 2009; 147 744 751
32. Chang HH, Lu MY, Liao YM et al. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent beta-thalassemia. Pediatr Blood Cancer: 2010; 56 420 424
33. Kang HJ, Lee JW, Choi J-Y et al. Pharmacogenetic Study of Deferasirox, An Iron Chelating Agent. ASH Annual Meeting Abstracts: 2010; 116 2060
34. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol: 2008; 83 858 861
35. Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol: 2011; 90 1 10